| PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: mechanism, combinations, and clinical outcome HO Alsaab, S Sau, R Alzhrani, K Tatiparti, K Bhise, SK Kashaw, AK Iyer Frontiers in pharmacology 8, 561, 2017 | 1639 | 2017 |
| Recent advances in hyaluronic acid-decorated nanocarriers for targeted cancer therapy JM Wickens, HO Alsaab, P Kesharwani, K Bhise, MCIM Amin, RK Tekade, ... Drug discovery today 22 (4), 665-680, 2017 | 178 | 2017 |
| Multifunctional nanoparticles for cancer immunotherapy: A groundbreaking approach for reprogramming malfunctioned tumor environment S Sau, HO Alsaab, K Bhise, R Alzhrani, G Nabil, AK Iyer Journal of controlled release 274, 24-34, 2018 | 150 | 2018 |
| Nanostructured lipid carriers employing polyphenols as promising anticancer agents: Quality by design (QbD) approach K Bhise, SK Kashaw, S Sau, AK Iyer International journal of pharmaceutics 526 (1-2), 506-515, 2017 | 99 | 2017 |
| Nano-engineered delivery systems for cancer imaging and therapy: Recent advances, future direction and patent evaluation G Nabil, K Bhise, S Sau, M Atef, HA El-Banna, AK Iyer Drug Discovery Today 24 (2), 462-491, 2019 | 92 | 2019 |
| PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: mechanism, combinations, and clinical outcome. Front Pharmacol. 2017; 8: 561 HO Alsaab, S Sau, R Alzhrani, K Tatiparti, K Bhise, SK Kashaw, AK Iyer Frontiers Media SA DOI 10, 2017 | 70 | 2017 |
| Nanomedicine for cancer diagnosis and therapy: Advancement, success and structure–activity relationship K Bhise, S Sau, H Alsaab, SK Kashaw, RK Tekade, AK Iyer Therapeutic delivery 8 (11), 1003-1018, 2017 | 61 | 2017 |
| Novel approaches for the treatment of methicillin-resistant Staphylococcus aureus: Using nanoparticles to overcome multidrug resistance K Vanamala, K Tatiparti, K Bhise, S Sau, MH Scheetz, MJ Rybak, D Andes, ... Drug discovery today 26 (1), 31-43, 2021 | 52 | 2021 |
| PDL-1 antibody drug conjugate for selective chemo-guided immune modulation of cancer S Sau, A Petrovici, HO Alsaab, K Bhise, AK Iyer Cancers 11 (2), 232, 2019 | 51 | 2019 |
| Improving the therapeutic efficiency of noncoding RNAs in cancers using targeted drug delivery systems R Alzhrani, HO Alsaab, A Petrovici, K Bhise, K Vanamala, S Sau, ... Drug discovery today 25 (4), 718-730, 2020 | 35 | 2020 |
| Combination of vancomycin and cefazolin lipid nanoparticles for overcoming antibiotic resistance of MRSA K Bhise, S Sau, R Kebriaei, SA Rice, KC Stamper, HO Alsaab, MJ Rybak, ... Materials 11 (7), 1245, 2018 | 24 | 2018 |
| Nano‐therapeutic strategies to target coronavirus MA Rauf, M Tasleem, K Bhise, K Tatiparti, S Sau, AK Iyer View 2 (3), 20200155, 2021 | 12 | 2021 |
| Development of extraction methods and quantification of Safranal by high performance liquid chromatography from Cuminum cyminum L. and studying its antimicrobial properties S Kulkarni, A Sane, K Bhise, A Patil, P Dhamole, S Desai International Congress on Environmental, Biotechnology, and Chemistry …, 2014 | 12 | 2014 |
| Folate Functionalized Lipid Nanoparticles for Targeted Therapy of Methicillin-Resistant Staphylococcus aureus K Vanamala, K Bhise, H Sanchez, R Kebriaei, D Luong, S Sau, ... Pharmaceutics 13 (11), 1791, 2021 | 11 | 2021 |
| Overcoming the tumor microenvironmental barriers of pancreatic ductal adenocarcinomas for achieving better treatment outcomes R Alzhrani, HO Alsaab, K Vanamala, K Bhise, K Tatiparti, A Barari, S Sau, ... Advanced therapeutics 4 (6), 2000262, 2021 | 11 | 2021 |
| Nanomaterials for tumor immunomodulation and overcoming current clinical challenges S Sau, R Alzhrani, K Bhise, HO Alsaab, SK Kashaw, AK Iyer Nanomedicine 14 (12), 1515-1519, 2019 | 3 | 2019 |
| Imaging the cellular components of the immune system for advancing diagnosis and immunotherapy of cancers K Bhise, S Sau, R Alzhrani, MA Rauf, K Tatiparti, AK Iyer Materials Today Advances 10, 100138, 2021 | 2 | 2021 |
| Drug delivery systems for treatment of infections AK Iyer, S Sau, M Rybak, K Bhise, R Kebriaei US Patent App. 16/958,647, 2020 | 2 | 2020 |
| Nanoparticles for Immune Cell Reprogramming and Reengineering of Tumor Microenvironment K Bhise, S Sau, R Alzhrani, AK Iyer Cell Reprogramming for Immunotherapy: Methods and Protocols, 211-221, 2020 | 2 | 2020 |
| 2391. Liposomal Vancomycin and Cefazolin Combinations for S. aureus Biofilms R Kebriaei, K Bhise, S Sau, S Rice, K Stamper, A Iyer, MJ Rybak Open Forum Infectious Diseases 5 (suppl_1), S713-S713, 2018 | 1 | 2018 |
